SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, today announced a summary of Contrave™ results at The Obesity Society’s Annual Scientific Meeting (NAASO) being held in New Orleans, October 20-24, 2007.* The Company presented both consolidated weight loss results from its Contrave Phase IIb trial and the first release of key secondary endpoint data. Contrave is one of the company’s two late-stage obesity drug candidates.
